Roswell Park Comprehensive Cancer Center

Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI

Retrieved on: 
Wednesday, November 1, 2023
Research, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Stem Cells, Other Technology, Health, Other Science, Chandos Chair of Medicine and Anatomy, FDA, CAR, CGMP, Associate, Ovarian cancer, Therapy, Roswell, II, Research and development, Translational research, Department of Medicine – University of Pamplona, Multimedia, Roswell Park Comprehensive Cancer Center, Senior, Alpha generation platform, Leukemia, Woman, Patient, Biomedicine, Lymphoma, Pharmaceutical industry, Roswell Park, Generate

In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.

Key Points: 
  • In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.
  • View the full release here: https://www.businesswire.com/news/home/20231101307318/en/
    Under the collaboration agreement, Generate:Biomedicines and Roswell Park will contribute toward creating optimized cell therapies, where a patient’s T cells are engineered to recognize and kill tumors.
  • The collaboration combines the programmability and scalability of The Generate Platform and Roswell Park’s expertise in cell therapy design, clinical development, and manufacturing to bring best-in-class cell therapies to patients.
  • It is anticipated that Roswell Park will serve as a site and recommend lead investigators for Phase I and II clinical trials.

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

Retrieved on: 
Saturday, October 14, 2023
Multimedia, M&T Bank, Priority review, Cancer, Glomus tumor, Food, Doctor of Philosophy, Hope, Research, Roswell Park Comprehensive Cancer Center, Texas Oncology, Ride, Multiple myeloma, Roswell, MD, Fred Hutchinson Cancer Research Center, National Cancer Institute, University, Survival, Disease, FDA, Glioblastoma, Accelerated approval (FDA), Fast track (FDA), NDA, Neurosurgery, Overlook Medical Center, Northwell Health, Journal, FTD, Fast Track, Assistant, PSA, Regulation of tobacco by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, Principal investigator, Prostate cancer, Brain, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical imaging, Medical device, Online shopping, DRS, Upstate New York, New York University, Roswell Park

BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The designation awarded to MimiVax Inc. provides more extensive and accelerated access to FDA resources for the company's development of the novel cancer immunotherapy SurVaxM, which is now in late-stage trials around the country.

Key Points: 
  • The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park.
  • BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .

AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Retrieved on: 
Friday, September 22, 2023
Roswell Park Comprehensive Cancer Center, AIM, Non-governmental organization, Roswell Park, NYSE, International Collaboration for the Care of the Elderly, Pharmaceutical industry

OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023.

Key Points: 
  • OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023.
  • In addition to the presentation, the Company is proud to announce its sponsorship of the event.
  • Details for the presentation are as follows:
    Session: Session 7: Team Science: National and International Collaborations with NGOs, Academia, Pharma, & Biotech
    For more information about the conference, visit: https://www.roswellpark.org/msc-symposium .
  • The presentation will be available on the AIM website once presented at the conference.

Cytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe

Retrieved on: 
Wednesday, September 20, 2023
CET, Education, Roswell Park Comprehensive Cancer Center, Research, Roswell Park, B-ALL, Flow cytometry, Knowledge, Diagnosis, LGC Ltd, European Society of Gynaecological Oncology, ICCS, Conference, Pharmaceutical industry

FREMONT, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, is furthering its mission to advance the next generation of high parameter cell analysis by continuing to have an active presence at key industry events worldwide.

Key Points: 
  • FREMONT, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, is furthering its mission to advance the next generation of high parameter cell analysis by continuing to have an active presence at key industry events worldwide.
  • The company’s Full Spectrum Profiling™ (FSP™) technology that streamlines workflows, accelerates discoveries and maximizes efficiency will be front and center at both the European Society for Clinical Cell Analysis’ (ESCCA) 2023 Conference in September and the 38 th International Clinical Cytometry (ICCS) Meeting & Course in October.
  • Cytek will be on hand at ESCCA 2023 in Utrecht, the Netherlands from September 27-30 to showcase its complete cell analysis solutions that enable scientists to advance their research, gain deeper insights, and fast-track discovery.
  • “Cancer treatment is an ever-evolving field, with clinical researchers and clinicians constantly striving to improve diagnostics and treatment,” said Dr. Ramirez.

Vera Bradley Foundation for Breast Cancer Raises $1,513,713 for Breast Cancer Research

Retrieved on: 
Monday, September 18, 2023
Volunteering, Partnership, Roswell Park Comprehensive Cancer Center, Indiana University School of Medicine, Hope, Research, University of Virginia Cancer Center, Breast Cancer Awareness Month, National Cancer Institute, Breast cancer, School, Classic, NCI, National Breast Cancer Foundation (Australia), Disease, Dietary supplement, Medicine

FORT WAYNE, Ind., Sept. 17, 2023 (GLOBE NEWSWIRE) -- The Vera Bradley Foundation for Breast Cancer (the "Foundation") today announced a donation of $1,513,713 to support the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine (“IU School of Medicine”).

Key Points: 
  • FORT WAYNE, Ind., Sept. 17, 2023 (GLOBE NEWSWIRE) -- The Vera Bradley Foundation for Breast Cancer (the "Foundation") today announced a donation of $1,513,713 to support the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine (“IU School of Medicine”).
  • The Foundation’s donation announcement was shared at the 29th annual Vera Bradley Foundation for Breast Cancer Classic (the “Classic”), which gathered guests, players, and volunteers from across the country to raise funds for breast cancer research.
  • More than 35 members of the Vera Bradley Foundation Center for Breast Cancer Research team at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center (the “IU Cancer Center”) work collaboratively with laboratory, clinical, translational and population/prevention researchers in a multi-disciplinary approach.
  • “For the past 30 years, the Vera Bradley Foundation for Breast Cancer has been steadfastly committed to raising funds for breast cancer research,” noted Stephanie Scheele, Executive Director of the Vera Bradley Foundation for Breast Cancer.

AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Bre

Retrieved on: 
Monday, September 11, 2023
CKM, TNBC, Roswell Park Comprehensive Cancer Center, Science of team science, AIM, IV, Senior, DL, Safety, DLT, SITC, Paclitaxel, Immunotherapy, Celecoxib, Cyclophosphamide, Trae tha Truth, Roswell Park, Research, AC, Neoplasm, Biomarker, Doctor of Philosophy, PCR, Assistant, NAC, Patient, Blood, Rintatolimod, Society for Immunotherapy of Cancer, Financial toxicity, Immunology, Infrared spectroscopy correlation table, Physician, NYSE, Medical imaging, Pharmaceutical industry, MD

OCALA, Fla., Sept. 11, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen® (rintatolimod) as a component of a CKM regimen for the treatment of early-stage triple negative breast cancer (TNBC). The complete topline results are now available on ClinicalTrials.gov: NCT04081389.

Key Points: 
  • The complete topline results are now available on ClinicalTrials.gov: NCT04081389 .
  • “We are pleased to bolster our growing body of data from Ampligen and the results demonstrated in the Phase 1 study with the completed topline data report now in hand.
  • Secondary endpoints included pCR rate where 5/9 (56%) of patients attained pCR and 1 more patient attained ypTmic.
  • For more information about the Phase 1 study, visit ClinicalTrials.gov: NCT04081389 .

Harbinger Health Expands Industry-Leading Executive Team

Retrieved on: 
Wednesday, September 6, 2023
Healthcare Businesswomen's Association, Human resources, Bachelor of Science in Human Biology, Pepperdine University, Genomic Health, Computing, Natural science, University, Industry Dive, University at Buffalo, Genomics, Engineering, Biotechnology, Abbott Laboratories, Chief commercial officer, North Carolina A&T State University, Cancer, Georgia State University, Electronics, Roswell Park Comprehensive Cancer Center, CMO, CCO, Exact sciences, Marketing, Uppsala University, Business administration, Acquisition, CBO, CFO, Growth, Master of Business Administration, Foundation Medicine, SVP, Cornell University, Manufacturing engineering, Harbinger, Data science, Management, Science, Pharmacy, Hologic, Biology, Anatomy

CAMBRIDGE, Mass., Sept. 6, 2023 /PRNewswire/ -- Harbinger Health, a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, announced today the appointment of Dymeka Harrison as Chief Commercial Officer (CCO), Mathew Sargent as Chief Business Officer (CBO), and Gisela Paulsen as Chief Operating Officer (COO), positioning the Company for continued growth and platform and product advancement.

Key Points: 
  • "Harbinger is laser-focused on our mission to create a new cancer screening paradigm by delivering accessible and low-cost early-stage screening tools," said Dr. Hahn.
  • Gisela Paulsen joined Harbinger as Chief Operating Officer, bringing over 25 years of expertise in the life sciences industry to the team.
  • She brings experience from executive roles at leading diagnostics companies Oncocyte Corporation, Exact Sciences (legacy Genomic Health) and Genentech/Roche across functions including commercial, program management, quality and regulatory, and other administrative functions.
  • Aside from her position at Harbinger Health, Ms. Paulsen is also Vice Chair of the Healthcare Businesswomen Association where she has led nominations, strategies and digital transformation committees.

ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor

Retrieved on: 
Wednesday, August 23, 2023
Columbia University, Talimogene laherparepvec, Clinical associates, Merkel-cell carcinoma, Immunotherapy, Associate, Rutgers University, Harvard Medical School, Journal, Rush University, Translational medicine, Patient, Compass, China Bio-Immunity Corporation, Hospital, FDA, Massachusetts General Hospital, Therapy, Roswell Park Comprehensive Cancer Center, Book, Dean (education), Pharmaceutical industry, Cancer, Research

SHENZHEN, China, Aug. 22, 2023 /PRNewswire/ -- ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor.

Key Points: 
  • SHENZHEN, China, Aug. 22, 2023 /PRNewswire/ -- ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor.
  • Dr. Kaufman is a leading authority on tumor immunotherapy and oncolytic virus.
  • "We are honored to have Dr. Kaufman as our Consulting Medical Advisor, to jointly explore clinical mechanisms and translational medicine of oncolytic virus, and provide professional advice for our future clinical development.
  • said Dr. Guoying Zhou, Chairman and CEO of ImmVira, "His insights will help us accelerate global clinical progress of oncolytic virus pipelines and meet medical needs of cancer patients as soon as possible."

LUNGevity Launches Early Lung Cancer Center to Accelerate the Early Diagnosis and Treatment of Lung Cancer

Retrieved on: 
Tuesday, August 1, 2023
IPN, Stern family, Pomerance, Therapy, Policy, Survival, Roswell Park Comprehensive Cancer Center, Lung cancer, Quality of life, Intelligence, Research, ELCC, AstraZeneca, Radiology, Friends, Patient, Thomas, Mortality, Incidental, Death, Family, Disease, Pharmaceutical industry, Medical imaging, Uranium mining

WASHINGTON, Aug. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, today announced the launch of its Early Lung Cancer Center (ELCC). The ELCC was created to accelerate the development and broad adoption of early detection and treatment options so people diagnosed with lung cancer have the best chance for long-term survival and a better quality of life.

Key Points: 
  • WASHINGTON, Aug. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, today announced the launch of its Early Lung Cancer Center (ELCC).
  • "The LUNGevity Early Lung Cancer Center is a multifaceted effort to improve lung cancer survival by making early detection and early disease management the norm.
  • "Early detection is key to improving lung cancer mortality," said Nabil Chehab, Medical Franchise Head, Lung Cancer at AstraZeneca.
  • "The goal of the Early Lung Cancer Center is to strategically amplify those efforts, while building synergies with our partners, to create a world where no one dies of lung cancer."

CoImmune Obtains License to Target DLL3 with IL-18 Armored CAR Technology

Retrieved on: 
Tuesday, June 27, 2023
SHIELD, Memorial Sloan Kettering Cancer Center, Roswell Park Comprehensive Cancer Center, Carcinoma, Interleukin, CIK, CD19, ALL, Acute lymphoblastic leukemia, Lymphoid leukemia, B cell, Armour, SCLC, CAR, Journal of Clinical Investigation, DLL3, Investigational New Drug, Chandos Chair of Medicine and Anatomy, MSK, PD-1, IND, Disease, Pharmaceutical industry, Vaccine

DURHAM, N.C., June 27, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced it has exercised its option to obtain an exclusive license in the Delta-like Ligand 3 (DLL3)-targeted, allogeneic Chimeric Antigen Receptor-Cytokine Induced Killer (CAR-CIK) cell therapy field to interleukin-18 (IL-18) Armored CAR technology under a prior agreement with Memorial Sloan Kettering Cancer Center (MSK). The company is coupling the technology with allogeneic CIK cells and launched a development program focused on solid tumors with initial trials planned in small cell lung cancer (SCLC).

Key Points: 
  • CoImmune has the option to select up to three targets for IL-18 CAR products in the allogeneic cell therapy field under the agreement with MSK.
  • In March 2023, the company announced it had selected CD19 as the first target to support the clinical development of CMN-008 (Armored CAR-CIK cells) in B-cell malignancies.
  • The DLL3 target has been identified as a tumor-specific cell surface marker on neuroendocrine cancers including SCLC.
  • We saw strong synergy with PD1 checkpoint inhibition, suggesting a potential for curative responses at lower, subtherapeutic administrations of IL-18 armored anti-DLL3 CAR T cells.